{"id":"https://openalex.org/W2085286133","doi":"https://doi.org/10.1111/bjh.12077","title":"Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy\u2010induced immunosuppression","display_name":"Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy\u2010induced immunosuppression","publication_year":2012,"publication_date":"2012-10-09","ids":{"openalex":"https://openalex.org/W2085286133","doi":"https://doi.org/10.1111/bjh.12077","mag":"2085286133","pmid":"https://pubmed.ncbi.nlm.nih.gov/23043283"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.12077","doi":"https://doi.org/10.1111/bjh.12077","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.12077","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090781165","display_name":"Sandra Eketorp Sylvan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sandra Eketorp Sylvan","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079025879","display_name":"Eva D. Rossmann","orcid":"https://orcid.org/0000-0002-3557-6013","observed_orcids":["https://orcid.org/0000-0002-3557-6013"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Eva Rossmann","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088953410","display_name":"Fariba Mozaffari","orcid":"https://orcid.org/0000-0002-7528-4381","observed_orcids":["https://orcid.org/0000-0002-7528-4381"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Fariba Mozaffari","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;","institution_ids":["https://openalex.org/I28166907"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111909350","display_name":"Anna Porwit\u2010MacDonald","orcid":"https://orcid.org/0000-0003-0709-2713","observed_orcids":["https://orcid.org/0000-0003-0709-2713"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anna Porwit","raw_affiliation_strings":["Department of Hematopathology, Karolinska University Hospital, Stockholm, Sweden","Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology, Karolinska University Hospital, Stockholm, Sweden","institution_ids":["https://openalex.org/I1335113835"]},{"raw_affiliation_string":"Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023386496","display_name":"Stefan Norin","orcid":"https://orcid.org/0000-0002-7056-9900","observed_orcids":["https://orcid.org/0000-0002-7056-9900"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Stefan Norin","raw_affiliation_strings":["Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden,","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089373395","display_name":"Claes Karlsson","orcid":"https://orcid.org/0009-0003-8971-2249","observed_orcids":["https://orcid.org/0009-0003-8971-2249"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Claes Karlsson","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071144394","display_name":"Lotta Hansson","orcid":"https://orcid.org/0000-0001-6614-5737","observed_orcids":["https://orcid.org/0000-0001-6614-5737"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Lotta Hansson","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043417410","display_name":"Jeanette Lundin","orcid":"https://orcid.org/0000-0002-4473-5450","observed_orcids":["https://orcid.org/0000-0002-4473-5450"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Jeanette Lundin","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049924304","display_name":"Anders \u00d6sterborg","orcid":"https://orcid.org/0000-0001-6489-4865","observed_orcids":["https://orcid.org/0000-0001-6489-4865"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anders \u00d6sterborg","raw_affiliation_strings":["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Departments of Hematology and Oncology Karolinska University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I1335113835"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5043417410"],"corresponding_institution_ids":["https://openalex.org/I1335113835","https://openalex.org/I28166907"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":1.0226,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.7728784,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"159","issue":"5","first_page":"0","last_page":"0"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9700000286102295},{"id":"https://openalex.org/keywords/alemtuzumab","display_name":"alemtuzumab","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4659999907016754},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.7049999833106995},{"id":"https://openalex.org/keywords/t-cell-stimulation","display_name":"T cell stimulation","score":0.5690000057220459},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.7990000247955322},{"id":"https://openalex.org/keywords/opportunistic-infection-prophylaxis","display_name":"opportunistic infection prophylaxis","score":0.8640000224113464},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.9509999752044678},{"id":"https://openalex.org/keywords/immune-monitoring","display_name":"immune monitoring","score":0.7129999995231628},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.3529999852180481},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.7943142056465149},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.776640772819519},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.6425257921218872},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.527543306350708},{"id":"https://openalex.org/C2780366003","wikidata":"https://www.wikidata.org/wiki/Q246147","display_name":"Cytopenia","level":3,"score":0.5176718235015869},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5173032283782959},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.49425530433654785},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.45539018511772156},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.43985307216644287},{"id":"https://openalex.org/C2908885563","wikidata":"https://www.wikidata.org/wiki/Q410130","display_name":"Aldesleukin","level":4,"score":0.4147319495677948},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.39568227529525757},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.39160746335983276},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.36487680673599243},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3075239062309265},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.27778035402297974},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.18329361081123352},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.10797333717346191}],"mesh":[{"descriptor_ui":"D000074323","descriptor_name":"Alemtuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007165","descriptor_name":"Immunosuppression Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.12077","doi":"https://doi.org/10.1111/bjh.12077","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.12077","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:23043283","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23043283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320322315","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W2012630504","https://openalex.org/W2012721290","https://openalex.org/W2025741975","https://openalex.org/W2029215138","https://openalex.org/W2043607649","https://openalex.org/W2066815159","https://openalex.org/W2068283826","https://openalex.org/W2100207540","https://openalex.org/W2136242714","https://openalex.org/W2143749371"],"related_works":["https://openalex.org/W2090035139","https://openalex.org/W2546805667","https://openalex.org/W2559725481","https://openalex.org/W2399916762","https://openalex.org/W2199025621","https://openalex.org/W2273526463","https://openalex.org/W2142604819","https://openalex.org/W2573028852","https://openalex.org/W2136597718","https://openalex.org/W2019274594"],"abstract_inverted_index":{"This":[0],"phase-I":[1,996],"trial":[2],"studied":[3],"low-dose":[4,494,1004],"lenalidomide":[5,1147],"(L)":[6],"as":[7,387,506,699,783,1015,1027],"an":[8,971,1016,1028],"immune":[9,498,604,1017],"stimulator":[10],"in":[11,25,69,287,470,512,626,670,725,755,769,814,871,885,966,978,994,1030,1059,1151],"refractory":[12],"chronic":[13],"lymphocytic":[14],"leukaemia":[15],"(CLL)":[16],"patients":[17,143,284,291,304,320,327,357,403,414,984,1119],"receiving":[18],"alemtuzumab":[19],"(A).":[20],"L":[21,40,115,122,129,208,232,243,309,324,378,479,495,612,658,965,993,1005,1010],"was":[22,44,186,206,209,222,272,349,397,453,484,500,534,606,682,711,744,875,882,990,1000,1035],"given":[23],"alone":[24,733],"weeks":[26,323,330],"1\u20134":[27,635],"and":[28,51,94,105,175,179,194,231,254,261,266,278,300,312,325,342,367,458,466,522,620,675,680,714,749,785,835,847,880,892,1006,1026,1053,1061,1093,1100,1112,1120,1125,1135],"then":[29],"together":[30],"with":[31,147,157,306,482,654,968,975,985,1020],"A":[32,42,91,136,221,246,483,531,547,664,691,732,867,969],"for":[33,38,155,333,841],"12":[34,247,329,407,939],"weeks.":[35,248],"The":[36,140,444,473,646,988,1033,1051,1153],"rationale":[37],"this":[39,756,995],"+":[41,192,940],"combination":[43,967],"based":[45],"on":[46,132,237,316,493,539,1003,1146],"the":[47,203,283,513,556,627,639,721,815,872,1040,1047,1056,1089,1095,1102,1110,1122,1128,1133,1137,1144],"following:":[48],"different":[49,845],"effector-functions":[50,126],"side-effects":[52],"(Aue":[53,787,851],"et":[54,58,62,72,76,80,84,88,102,391,432,437,735,739,788,792,804,808,852,856,860],"al,":[55,59,63,73,77,81,85,89,103,392,433,438,736,740,789,793,805,809,853,857,861],"2009;":[56,790,854],"Lapalombella":[57,791],"2010;":[60,806],"Lee":[61,859],"2011);":[64],"they":[65],"are":[66,285,468,768],"both":[67,540],"active":[68],"CLL":[70,149,779],"(Keating":[71,734],"2002;":[74,737],"Lundin":[75,738],"2004;":[78],"Chanan-Khan":[79],"2006;":[82,86],"Osterborg":[83],"Ferrajoli":[87],"2008);":[90],"reduces":[92],"T-":[93],"natural":[95],"killer":[96],"(NK)-cells":[97],"to":[98,263,274,383,617,762,771,826,832,869,1066,1158],"low":[99],"numbers":[100,672,754],"(Lundin":[101],"2004)":[104],"opportunistic":[106],"infections":[107,118],"occur":[108],"mainly":[109],"at":[110,211,224,255,544,577,595,650,684,692,709],"T-cell":[111,747,886,998],"nadirs":[112],"\u2013":[113],"if":[114],"stimulates/maintains":[116],"T-cells,":[117],"may":[119,123,427],"be":[120,1012],"prevented;":[121],"potentiate":[124],"A's":[125],"by":[127,508,536,1037],"NK-stimulation;":[128],"is":[130,381,1140],"effective":[131],"enlarged":[133],"lymph-nodes":[134,299],"whereas":[135],"eradicates":[137],"blood/bone-marrow":[138],"CLL-cells.":[139],"study":[141,727,758,874,1034,1111],"included":[142,190,258,336],"(n":[144,339,344],"=":[145,340,345,660],"12)":[146],"chemotherapy-refractory":[148],"or":[150,216,888,1023],"who":[151],"were":[152,292,450,759],"not":[153,631,667,798],"suitable":[154],"treatment":[156,240,548,643],"fludarabine":[158],"(haemolytic":[159],"anaemia,":[160],"del17p,":[161],"severe":[162],"cytopenia).":[163],"Neutrophils":[164],"\u22650\u00b75":[165],"\u00d7":[166,170,716],"109/l,":[167,171],"platelets":[168],"\u226525":[169],"creatinine":[172],"\u2264177":[173],"\u03bcmol/l":[174,178],"bilirubin":[176],"\u226426":[177],"World":[180],"Health":[181],"Organization":[182],"Performance":[183],"Score":[184],"\u22642":[185],"required.":[187],"Infection":[188],"prophylaxis":[189],"cotrimoxazole":[191],"valaciclovir":[193],"granulocyte":[195,204],"colony-stimulating":[196],"factor":[197],"(300":[198],"\u03bcg/s.c.":[199],"per":[200],"tiw)":[201],"unless":[202],"count":[205],"normal.":[207],"started":[210,315],"2\u00b75":[212,307],"mg/d":[213,218],"(Patients":[214,219,409],"1\u20136)":[215],"5":[217,226,317,398],"7\u201312).":[220],"added":[223],"week":[225,578,596,634,651,685,693,819],"(30":[227],"mg":[228,308,364,370,992],"tiw":[229],"s.c)":[230],"escalated":[233],"(5\u201310\u201315":[234],"mg/d)":[235],"depending":[236],"tolerability.":[238],"Maximum":[239],"periods":[241],"were:":[242],"16":[244,322],"weeks,":[245,505],"Immunomonitoring":[249],"(baseline,":[250],"end":[251,545],"cycle-1":[252],"(EndC1)/week-4":[253],"end-of-treatment":[256],"(EoT)":[257],"flow":[259],"cytometry":[260],"T-cell-response":[262],"purified-protein-derivative":[264],"(PPD)":[265],"phytohaemagglutinin":[267],"(PHA).":[268],"Wilcoxon":[269],"signed-rank":[270],"test":[271],"used":[273],"compare":[275],"baseline,":[276],"EndC1":[277],"EoT.":[279],"Clinical":[280,1074],"characteristics":[281],"of":[282,362,420,478,515,546,558,575,602,629,641,648,657,673,705,778,849,981,1073,1077,1143],"shown":[286,469,616],"Table":[288,471],"1.":[289,472],"Most":[290],"elderly,":[293],"had":[294,404,441,1156],"advanced-phase":[295,986],"unmutated":[296],"CLL,":[297],"large":[298],"poor-prognosis":[301,983],"cytogenetics.":[302],"4/6":[303],"treated":[305,1118,1130],"progressed":[310],"early":[311,334,385,492,603,1002],"Patients":[313],"7\u201312":[314],"mg/d.":[318],"6/12":[319],"completed":[321,328],"9/12":[326],"A.":[331],"Reasons":[332],"withdrawal":[335],"progressive":[337],"disease":[338],"3)":[341],"neutropenia":[343,907,919,926],"3).":[346],"Response":[347],"rate":[348],"42%":[350],"[5/12,":[351],"all":[352,419,695],"partial":[353],"remission":[354],"(PR)].":[355],"Responding":[356],"received":[358],"a":[359,375,455,509,571,591,623,764,812,1141],"median":[360,703,821],"L-dose":[361,846],"495":[363],"(range":[365,371,400,878],"42\u2013625)":[366],"non-responders":[368],"162":[369],"50\u2013532),":[372],"suggesting":[373],"that":[374,425],"relatively":[376],"high":[377],"starting":[379],"dose":[380,476,656,868],"required":[382],"avoid":[384],"progression,":[386],"previously":[388,614],"reported":[389,775],"(Badoux":[390],"2011).":[393,439,862],"Median":[394,863],"progression-free-survival":[395],"(PFS)":[396],"months":[399,408,877],"1\u201321+);":[401],"three":[402],"PFS":[405],"exceeding":[406],"5,":[410,694],"6,":[411],"8).":[412],"Four":[413],"developed":[415],"transient":[416],"tumour-flare-reaction":[417],"(TFR)":[418],"whom":[421],"achieved":[422],"PR,":[423],"supporting":[424],"TFR":[426,467],"precede":[428],"clinical":[429,750,976],"responses":[430,887],"(Chanan-Khan":[431],"2006,":[434],"2011;":[435,858],"Badoux":[436,807,855],"None":[440],"tumour-lysis-syndrome":[442],"(TLS).":[443],"most":[445,488],"common":[446],"grade":[447,463],"III-IV":[448,464],"adverse-events":[449],"neutropenia,":[451],"which":[452,774],"also":[454,637],"dose-limiting":[456],"toxicity,":[457],"thrombocytopenia":[459],"(75%":[460],"each).":[461],"Non-haematological":[462],"toxicity":[465],"maximum":[474],"tolerated":[475],"(MTD)":[477],"when":[480],"combined":[481,642],"10":[485,991],"mg/d,":[486],"but":[487,636,666,752,811],"side":[489],"effects":[490],"occurred":[491],"alone.":[496],"L-induced":[497,776],"stimulation":[499,605,999],"already":[501],"apparent":[502],"after":[503,731],"4":[504,579,597,652,686],"indicated":[507],"significant":[510],"increase":[511,669],"proportion":[514,557,574,628],"activated":[516,559],"(HLA-DR+)":[517,560],"CD4":[518,674,723],"(P":[519,524,549,580,659],"<":[520,525,550,581],"0\u00b701)":[521],"CD8":[523,567,676],"0\u00b705)":[526,551,582],"T":[527,541,568,585],"cells":[528,562,569],"(Fig":[529,552,583,644,662,678,687],"1A).":[530,553],"sustained":[532],"activation":[533,748],"revealed":[535],"HLA-DR":[537],"coexpression":[538],"cell":[542,586,707],"subsets":[543,697],"In":[554,963],"contrast,":[555],"NK":[561],"remained":[563,837],"unchanged":[564],"(not":[565,598],"shown).":[566,599],"showed":[570,590,970],"significantly":[572],"increased":[573],"CD28-expression":[576],"1B).":[584],"proliferation":[587],"(PPD/PHA":[588],"stimulation)":[589],"non-significant":[592],"increasing":[593,800],"trend":[594,813],"Additional":[600],"evidence":[601],"evident":[607],"among":[608],"regulatory":[609],"T-cells":[610,677],"(Treg).":[611],"has":[613],"been":[615],"decrease":[618,625],"Treg":[619,630,1007],"we":[621,796],"observed":[622,683,745],"gradual":[624],"only":[632],"during":[633,818],"over":[638],"course":[640],"1C).":[645],"magnitude":[647],"change":[649],"correlated":[653],"cumulative":[655],"0\u00b702)":[661],"1D).":[663],"numerical,":[665],"significant,":[668],"absolute":[671],"1E)":[679],"NK-cells":[681],"1F).":[688],"After":[689],"adding":[690],"lymphoid":[696],"were,":[698],"expected,":[700],"markedly":[701],"reduced:":[702],"number":[704],"each":[706],"subset":[708],"EoT":[710,722],"0\u00b719,":[712],"0\u00b7054":[713],"0":[715],"109":[717],"cells/l,":[718],"respectively.":[719],"Notably,":[720],"counts":[724],"our":[726,766],"appears":[728],"higher":[729],"than":[730],"2004).":[741],"No":[742],"relationship":[743],"between":[746,890],"response,":[751],"patient":[753],"phase-1":[757],"too":[760],"small":[761],"draw":[763],"conclusion.":[765],"results":[767],"contrast":[770],"previous":[772],"studies,":[773],"upregulation":[777],"co-stimulatory":[780],"molecules,":[781],"such":[782],"CD80/86/40":[784],"Fas-L":[786],"2010).":[794],"Similarly,":[795],"could":[797],"confirm":[799],"immunoglobulin":[801],"levels":[802],"(Lapalombella":[803],"2011),":[810],"opposite":[816],"direction":[817],"1\u20134;":[820],"IgG":[822],"decreased":[823],"from":[824,830,865,1039],"3\u00b77":[825],"3\u00b74":[827],"g/l,":[828,834],"IgA":[829],"0\u00b749":[831],"0\u00b736":[833],"IgM":[836],"stable.":[838],"Possible":[839],"explanations":[840],"these":[842],"discrepancies":[843],"include":[844],"length":[848],"therapy":[850],"time":[864],"last":[866],"inclusion":[870],"present":[873],"30":[876],"16\u201399)":[879],"there":[881],"no":[883],"difference":[884],"Ig-patterns":[889],"A-pretreated":[891],"-naive":[893],"patients.":[894],"17p(24)":[895],"13q(96)":[896],"11q(99)":[897],"11q(81)":[898],"17p(30)":[899],"13q(63)":[900],"Pneumonia":[901],"(III)":[902,908,910,914,917,920,927,934,937,946,958,962],"Tumour":[903,922,942,953],"flare":[904,923,943,954],"(I)":[905],"Febrile":[906,918,925],"Thrombosis":[909,913],"17p(21)":[911],"11q(65)":[912],"CMV":[915,928,947,950],"reactivation":[916,929,948,951],"x2":[921],"(II)":[924,930,944,949,952,955],"13q(90)":[931],"11q(90)":[932],"Hypotension":[933],"Elevated":[935],"potassium":[936],"17p(10)":[938],"(68)":[941],"Diarrhoea":[945],"Ventricular":[956],"arrhythmia":[957],"Congestive":[959],"heart":[960],"failure":[961],"summary,":[964],"acceptable":[972],"safety":[973],"profile":[974],"activity":[977],"approximately":[979],"half":[980],"elderly":[982],"CLL.":[987,1152],"MTD":[989],"trial.":[997],"obtained":[1001],"decreased.":[1008],"Low-dose":[1009],"should":[1011],"further":[1013],"explored":[1014],"enhancing":[1018],"agent":[1019],"monoclonal":[1021],"antibodies":[1022],"anti-tumour":[1024],"agents":[1025],"adjuvant":[1029],"vaccination":[1031],"trials.":[1032],"supported":[1036],"funding":[1038],"Karolinska":[1041,1082],"Institutet":[1042],"Foundations,":[1043],"Stockholm":[1044,1060],"County":[1045],"Council,":[1046],"Swedish":[1048],"Cancer":[1049,1052,1057],"Society,":[1050],"Allergy":[1054],"Foundation,":[1055],"Society":[1058],"Celgene":[1062],"Inc.":[1063],"Special":[1064],"thanks":[1065],"biomedical":[1067],"scientist":[1068],"Maria":[1069],"B":[1070],"Larsson,":[1071],"Dept":[1072],"pathology/cytology,":[1075],"Division":[1076],"Haematopathology,":[1078],"Flow":[1079],"cytometric":[1080],"laboratory,":[1081],"University":[1083],"Hospital":[1084],"Solna,":[1085],"Stockholm.":[1086],"SES":[1087],"coordinated":[1088],"study,":[1090,1129],"analysed":[1091,1098,1113,1132],"data":[1092,1099,1134],"wrote":[1094,1101,1121,1136],"manuscript.":[1096,1103,1123,1138],"ER":[1097],"FM":[1104],"performed":[1105],"lab":[1106],"analyses.":[1107],"AP":[1108],"designed":[1109,1127],"results.":[1114],"SN,":[1115],"CK,":[1116],"LH":[1117],"JL":[1124],"A\u00d6":[1126,1139],"patients,":[1131],"member":[1142],"DMC":[1145],"phase":[1148],"III":[1149],"trials":[1150],"other":[1154],"authors":[1155],"nothing":[1157],"disclose.":[1159]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2016-06-24T00:00:00"}